Apr 30, 2025 / 07:00AM GMT
Matts Johansen - Aker Biomarine ASA - Chief Executive Officer
Good morning and welcome to the presentation of Aker Biomarine's results for the first quarter 2025 where myself, Matts Johansen, the CEO, and the CFO Katrine Klaveness will take you through the financials and the highlights of the quarter.
Another good quarter for Aker Biomarine, delivering close to $51 million of revenue of 5% from the same quarter last year, and a significant improvement on the EBITDA, up 59% from the same quarter last year. Schumann has ingredient continue positive development, 16% growth on the top line and 36% growth on the EBITDA and it's good to see consumer health products also back into growth territory. Human health ingredients continue its focus on getting closer to breakeven and deliver $0.4 million negative EBITDA with stable revenue, one step closer to that breakeven point.
Key milestone for the quarter is that we have kicked off the first human clinical trial for our new Lysoveta product that will eventually, if successful, generate the first health claims for the new brain ingredient that we
Q1 2025 Aker Biomarine ASA Earnings Call Transcript
Apr 30, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers